A detailed history of Abound Wealth Management transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Abound Wealth Management holds 1 shares of CRL stock, worth $215. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$215
Previous $255,000 4.71%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Aug 08, 2024

SELL
$203.52 - $273.43 $1,831 - $2,460
-9 Reduced 90.0%
1 $334,000
Q3 2023

Aug 08, 2024

SELL
$194.44 - $217.61 $194 - $217
-1 Reduced 9.09%
10 $1.96 Million
Q2 2023

Aug 08, 2024

BUY
$183.71 - $210.25 $183 - $210
1 Added 10.0%
11 $2.31 Million
Q1 2023

Aug 07, 2024

BUY
$191.89 - $259.92 $1,918 - $2,599
10 New
10 $2.02 Million

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $11B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Abound Wealth Management Portfolio

Follow Abound Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abound Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Abound Wealth Management with notifications on news.